{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T16:32:15Z","timestamp":1771605135620,"version":"3.50.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To evaluate the association of different contraceptive methods on the incidence and severity of acne.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>Using a de-identified commercial claims database, we performed a retrospective cohort study evaluating the incidence of clinical encounters for acne in the first year after initiation of contraception among female patients aged 12\u201340 years who were new contraceptive users. To evaluate the association of contraception class with acne severity, a subgroup analysis was performed among a cohort of patients with a history of acne examining the incidence of treatment escalation from topical acne medications to an oral tetracycline-class antibiotic in the year after initiation of contraception.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>Among new contraceptive users with no history of acne (N=336,738), compared with combined oral contraceptives (OCs), the copper intrauterine device (IUD) (hazard ratio [HR] 1.14; 95% CI 1.01\u20131.29) and levonorgestrel IUDs (HR 1.09; 95% CI 1.03\u20131.16) were associated with increased risk of clinical encounters with acne. Among those with a history of acne (n=21,178), compared with combined OCs, the copper IUD (HR 1.44; 95% CI 1.00\u20132.06) and levonorgestrel IUDs (HR 1.34; 95% CI 1.10\u20131.64) were associated with increased risk of treatment escalation from topical acne medications to an oral tetracycline class antibiotic.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Combined OCs appear to be associated with a modest (or small) protective effect with respect to incident acne and treatment escalation compared with other contraceptive methods. However, absolute differences between contraceptive methods were small.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000003880","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T20:41:03Z","timestamp":1588970463000},"page":"1306-1312","source":"Crossref","is-referenced-by-count":20,"title":["Influence of Contraception Class on Incidence and Severity of Acne Vulgaris"],"prefix":"10.1097","volume":"135","author":[{"given":"John S.","family":"Barbieri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nandita","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Margolis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia C.","family":"Harper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrina","family":"Abuabara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230711","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1440-0960.1997.tb01126.x","article-title":"Descriptive epidemiology of acne vulgaris in the community","volume":"38","author":"Stathakis","year":"1997","journal-title":"Australas J Dermatol"},{"key":"R2-20230711","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jaad.2007.06.045","article-title":"The prevalence of acne in adults 20 years and older","volume":"58","author":"Collier","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R3-20230711","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40257-016-0245-x","article-title":"Oral spironolactone for acne vulgaris in adult females: a hybrid systematic review","volume":"18","author":"Layton","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"R4-20230711","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.sder.2008.06.002","article-title":"Hormonal therapy for acne","volume":"27","author":"George","year":"2008","journal-title":"Semin Cutan Med Surg"},{"key":"R5-20230711","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0029-7844(97)00059-8","article-title":"Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial","volume":"89","author":"Redmond","year":"1997","journal-title":"Obstet Gynecol"},{"key":"R6-20230711","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/AOG.0b013e318187e1c5","article-title":"Treatment of acne using a 3-milligram drospirenone\/20-microgram ethinyl estradiol oral contraceptive administered in a 24\/4 regimen: a randomized controlled trial","volume":"112","author":"Maloney","year":"2008","journal-title":"Obstet Gynecol"},{"key":"R7-20230711","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejogrb.2010.12.027","article-title":"Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 \u03bcg plus drospirenone 3mg administered in a 24\/4 regimen: a pooled analysis","volume":"155","author":"Koltun","year":"2011","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R9-20230711","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaad.2017.04.016","article-title":"Trends in prescribing behavior of systemic agents used in the treatment of acne among dermatologists and nondermatologists: a retrospective analysis, 2004-2013","volume":"77","author":"Barbieri","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R10-20230711","first-page":"2","article-title":"The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea","volume":"69","author":"van Vloten","year":"2002","journal-title":"Cutis"},{"key":"R11-20230711","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2165\/11535450-000000000-00000","article-title":"Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study","volume":"30","author":"Kelly","year":"2010","journal-title":"Clin Drug Investig"},{"key":"R12-20230711","first-page":"123","article-title":"Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment","volume":"74","author":"Thorneycroft","year":"2004","journal-title":"Cutis"},{"key":"R13-20230711","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3109\/13625187.2011.614029","article-title":"Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17\u03b2-oestradiol in a 24\/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21\/7 regimen","volume":"16","author":"Mansour","year":"2011","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"R14-20230711","first-page":"670","article-title":"Hormonal contraceptives and acne: a retrospective analysis of 2147 patients","volume":"15","author":"Lortscher","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"R15-20230711","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.fertnstert.2008.02.140","article-title":"Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials","volume":"91","author":"Darney","year":"2009","journal-title":"Fertil Steril"},{"key":"R16-20230711","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/01.AOG.0000435452.86108.59","article-title":"Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use","volume":"122","author":"Grunloh","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R17-20230711","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.contraception.2017.07.097","article-title":"Young women's experience of side effects and contraceptive discontinuation","volume":"96","author":"Ayadi","year":"2017","journal-title":"Contraception"},{"key":"R18-20230711","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.contraception.2016.11.005","article-title":"A single-arm phase III study exploring the efficacy and safety of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5 mg), in an Asia-Pacific population","volume":"95","author":"Fan","year":"2017","journal-title":"Contraception"},{"key":"R19-20230711","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/AOG.0000000000003034","article-title":"Five-year contraceptive efficacy and safety of a levonorgestrel 52-mg intrauterine system","volume":"133","author":"Teal","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R20-20230711","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1093\/humrep\/dev221","article-title":"A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls","volume":"30","author":"Bahamondes","year":"2015","journal-title":"Hum Reprod Oxf Engl"},{"key":"R21-20230711","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.contraception.2003.11.008","article-title":"Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study","volume":"69","author":"Suhonen","year":"2004","journal-title":"Contraception"},{"key":"R23-20230711","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1684\/ejd.2015.2606","article-title":"Validating the diagnostic code for acne in a tertiary care dermatology centre","volume":"25","author":"Ejaz","year":"2015","journal-title":"Eur J Dermatol EJD"},{"key":"R24-20230711","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris","volume":"74","author":"Zaenglein","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R25-20230711","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamadermatol.2015.4498","article-title":"Cutaneous findings and systemic associations in women with polycystic ovary syndrome","volume":"152","author":"Schmidt","year":"2016","journal-title":"JAMA Dermatol"},{"key":"R26-20230711","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"R27-20230711","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet Lond Engl"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000003880","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T21:28:15Z","timestamp":1689110895000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000003880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000003880","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}